The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.
anti TNF-a
etanercept
infliximab
interleukin-6
nnarrative review
polymyalgia rheumatica
tumor necrosis factor alfa
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
22 Feb 2022
22 Feb 2022
Historique:
received:
28
01
2022
revised:
16
02
2022
accepted:
21
02
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR) therapy, but their long-term use (as is usually necessary in PMR patients) can induce many adverse events. Alternatives have long been sought. The primary aim of our narrative review is to provide an overview about the use of anti-tumor necrosis factor alpha (TNF-α) drugs in patients with PMR, and discuss advantages and disadvantages. we performed a non-systematic literature search (PRISMA protocol not followed) on PubMed and Medline (OVID interface). only two anti TNF-α drugs have been prescribed to PMR patients: infliximab in 62 patients and etanercept in 28 patients. These drugs were normally used in addition to GCs when significant comorbidities and/or relapsing PMR were present; less commonly, they were used as first-line therapy. In general, they have been scarcely successful in patients with PMR. Indeed, randomized controlled trials did not confirm the positive results reported in case reports and/or case series. However, an administration schedule and study design different from those proposed in the past could favour new scenarios in the interest of PMR patients.
Sections du résumé
BACKGROUND
BACKGROUND
Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR) therapy, but their long-term use (as is usually necessary in PMR patients) can induce many adverse events. Alternatives have long been sought. The primary aim of our narrative review is to provide an overview about the use of anti-tumor necrosis factor alpha (TNF-α) drugs in patients with PMR, and discuss advantages and disadvantages.
MATERIALS AND METHODS
METHODS
we performed a non-systematic literature search (PRISMA protocol not followed) on PubMed and Medline (OVID interface).
RESULTS AND CONCLUSIONS
CONCLUSIONS
only two anti TNF-α drugs have been prescribed to PMR patients: infliximab in 62 patients and etanercept in 28 patients. These drugs were normally used in addition to GCs when significant comorbidities and/or relapsing PMR were present; less commonly, they were used as first-line therapy. In general, they have been scarcely successful in patients with PMR. Indeed, randomized controlled trials did not confirm the positive results reported in case reports and/or case series. However, an administration schedule and study design different from those proposed in the past could favour new scenarios in the interest of PMR patients.
Identifiants
pubmed: 35330329
pii: jpm12030329
doi: 10.3390/jpm12030329
pmc: PMC8953282
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Reumatologia. 2020;58(6):381-389
pubmed: 33456081
Ann Intern Med. 2017 May 2;166(9):ITC65-ITC80
pubmed: 28460395
RMD Open. 2015 Nov 27;1(1):e000162
pubmed: 26635968
J Rheumatol. 2012 Mar;39(3):552-7
pubmed: 22247343
Medicines (Basel). 2018 Aug 01;5(3):
pubmed: 30071590
J Rheumatol. 2003 Apr;30(4):760-3
pubmed: 12672196
Arthritis Care Res (Hoboken). 2017 Aug;69(8):1282-1285
pubmed: 27768840
Rheumatology (Oxford). 2009 Feb;48(2):93-5
pubmed: 18658202
Arthritis Rheumatol. 2016 Oct;68(10):2550-4
pubmed: 27159185
J Rheumatol. 2021 Dec;48(12):1888-1889
pubmed: 34526393
Semin Arthritis Rheum. 2020 Jun;50(3):521-525
pubmed: 32107035
Arthritis Rheum. 2012 Apr;64(4):943-54
pubmed: 22389040
Eur Rev Med Pharmacol Sci. 2005 Nov-Dec;9(6):373-8
pubmed: 16479743
Eur J Biochem. 1991 Nov 15;202(1):3-14
pubmed: 1657606
Scott Med J. 2015 Feb;60(1):50-7
pubmed: 25201886
Autoimmun Rev. 2022 Feb;21(2):102995
pubmed: 34798314
J Rheumatol. 2021 Sep;48(9):1354
pubmed: 34074681
Clin Rheumatol. 2022 Jan;41(1):19-31
pubmed: 34415462
Clin Rheumatol. 2021 Oct;40(10):4367-4368
pubmed: 34460020
J Rheumatol. 2006 Apr;33(4):703-8
pubmed: 16583473
Semin Arthritis Rheum. 2020 Oct;50(5):1040-1048
pubmed: 32911281
Ann Rheum Dis. 1981 Feb;40(1):1-5
pubmed: 7469518
Ann Rheum Dis. 2015 Oct;74(10):1799-807
pubmed: 26359488
J Rheumatol. 1992 Feb;19(2):270-2
pubmed: 1629826
Ann Rheum Dis. 2010 Jan;69(1):263-9
pubmed: 19254903
Sci Rep. 2021 Mar 18;11(1):6220
pubmed: 33737697
Ann N Y Acad Sci. 2006 Jun;1069:307-14
pubmed: 16855158
J Rheumatol. 2017 Nov;44(11):1754-1758
pubmed: 28365575
Arthritis Res Ther. 2016 Jul 26;18(1):174
pubmed: 27455959
Methods Mol Biol. 2021;2130:29-51
pubmed: 33284434
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):675-81
pubmed: 11138328
Semin Arthritis Rheum. 1984 May;13(4):322-8
pubmed: 6729485
Reumatismo. 2018 Mar 27;70(1):10-17
pubmed: 29589398
Nat Rev Rheumatol. 2020 Sep;16(9):481-495
pubmed: 32759996
Rheumatol Int. 2018 Sep;38(9):1699-1704
pubmed: 29946742
Drugs Aging. 2019 Nov;36(11):1015-1026
pubmed: 31493201
Lancet. 2017 Oct 7;390(10103):1700-1712
pubmed: 28774422
Semin Arthritis Rheum. 2020 Oct;50(5):1131-1139
pubmed: 32920326
Arthritis Res Ther. 2010;12(5):R176
pubmed: 20854662
Reumatologia. 2021;59(6):425-426
pubmed: 35280453
Ann Intern Med. 2007 May 1;146(9):631-9
pubmed: 17470831
Arthritis Rheum. 2009 Oct 15;61(10):1454-61
pubmed: 19790127
Int J Rheum Dis. 2019 Dec;22(12):2151-2157
pubmed: 31625288
Arthritis Rheum. 2000 Aug;43(8):1749-55
pubmed: 10943865
J Biol Rhythms. 2015 Aug;30(4):277-90
pubmed: 25900041
Reumatologia. 2016;54(5):236-238
pubmed: 27994267
Arthritis Rheum. 2010 Dec;62(12):3768-75
pubmed: 20812339
Arthritis Rheum. 2007 Dec 15;57(8):1514-9
pubmed: 18050171
Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S9-11
pubmed: 10948749
Cytokine Growth Factor Rev. 2019 Apr;46:10-16
pubmed: 31000463
Eur J Rheumatol. 2017 Jun;4(2):157-160
pubmed: 28638694
Indian J Med Res. 2017 May;145(5):593-600
pubmed: 28948949
Autoimmun Rev. 2020 Nov;19(11):102670
pubmed: 32942037
Clin Rheumatol. 2012 Mar;31(3):575-9
pubmed: 22234490
RMD Open. 2017 Mar 17;3(1):e000426
pubmed: 28405475
Clin Rheumatol. 2016 May;35(5):1367-75
pubmed: 24803231
Med Sci (Basel). 2019 Aug 30;7(9):
pubmed: 31480261
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):655-8
pubmed: 11138324
Reumatismo. 2018 Mar 27;70(1):44-50
pubmed: 29589402
Ann Rheum Dis. 2018 Dec;77(12):1750-1756
pubmed: 30297332